Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

2023349 citationsJournal Article

Authors

Cornelia Liedtke · Institut Gustave Roussy

Chafika Mazouni · Institut Gustave Roussy

Kenneth R. Hess · Institut Gustave Roussy

Fabrice André · The University of Texas MD Anderson Cancer Center

Attila Tordai · The University of Texas MD Anderson Cancer Center

Jaime Mejia · Institut Gustave Roussy

W. Fraser Symmans

Abstract

Patients with TNBC have increased pCR rates compared with non-TNBC, and those with pCR have excellent survival. However, patients with RD after neoadjuvant chemotherapy have significantly worse survival if they have TNBC compared with non-TNBC, particularly in the first 3 years.

Topics & Keywords

Breast Cancer Treatment Studies Cancer Treatment and Pharmacology HER2/EGFR in Cancer Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 41, Issue 10, pp. 1809-1815

DOI: 10.1200/jco.22.02572

Field-Weighted Citation Impact: 35.50